Michler, T. ; Zillinger, J. ; Hagen, P. ; Cheng, F. ; Festag, J. ; Kosinska, A. ; Protzer, U.
The lack of HBsAg secretion does neither facilitate induction of antiviral T cell responses nor Hepatitis B Virus clearance in mice.
Antiviral Res. 226:105896 (2024)
Xie, Z. ; Protzer, U.
Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B.
Antiviral Res. 229:105972 (2024)
Ko, C. ; Su, J. ; Festag, J. ; Bester, R. ; Kosinska, A. ; Protzer, U.
Intramolecular recombination enables the formation of hepatitis B virus (HBV) cccDNA in mice after HBV genome transfer using recombinant AAV vectors.
Antiviral Res. 194, 05140:105140 (2021)
Svilenov, H.L.* ; Sacherl, J. ; Reiter, A.* ; Wolff, L.S. ; Cheng, C.-C. ; Stern, M.* ; Grass, V. ; Feuerherd, M. ; Wachs, F.P.* ; Simonavicius, N.* ; Pippig, S.* ; Wolschin, F.* ; Keppler, O.T.* ; Buchner, J.* ; Brockmeyer, C.* ; Protzer, U.
Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein.
Antiviral Res. 196:105197 (2021)
Tan, A.T.* ; Schreiber, S.
Adoptive T-cell therapy for HBV-associated HCC and HBV infection.
Antiviral Res. 176:104748 (2020)
Xia, Y. ; Schlapschy, M.* ; Morath, V.* ; Röder, N. ; Vogt, E.I.* ; Stadler, D. ; Cheng, X. ; Dittmer, U.* ; Sutter, K.* ; Heikenwälder, M. ; Skerra, A.* ; Protzer, U.
PASylated interferon α efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice.
Antiviral Res. 161, 134-143 (2019)
Esser, K. ; Lucifora, J. ; Wettengel, J.M. ; Singethan, K. ; Glinzer, A.* ; Zernecke, A.* ; Protzer, U.
Lipase inhibitor orlistat prevents hepatitis B virus infection by targeting an early step in the virus life cycle.
Antiviral Res. 151, 4-7 (2018)
Golsaz-Shirazi, F.* ; Amiri, M.M.* ; Farid, S.* ; Bahadori, M.* ; Bohne, F. ; Altstetter, S. ; Wolff, L. ; Kazemi, T.* ; Khoshnoodi, J.* ; Hojjat-Farsangi, M.* ; Chudy, M.* ; Jeddi-Tehrani, M.* ; Protzer, U. ; Shokri, F.*
Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg).
Antiviral Res. 144, 153-163 (2017)
Yin, R.* ; Liu, X.* ; Zhang, P.* ; Chen, Y.* ; Xie, G.* ; Ai, L.* ; Xue, C.* ; Qian, J.* ; Bi, Y.* ; Chen, J.* ; Sun, Y.* ; Stöger, T. ; Ding, Z.*
A Raf kinase inhibitor demonstrates antiviral activities both in vitro and in vivo against different genotypes of virulent Newcastle disease virus.
Antiviral Res. 133, 140-144 (2016)
Zhang, E.* ; Kosinska, A. ; Lu, M.* ; Yan, H.* ; Roggendorf, M.
Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA.
Antiviral Res. 123, 193-203 (2015)
Lucifora, J. ; Esser, K. ; Protzer, U.
Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes.
Antiviral Res. 97, 195-197 (2013)